Clinical Trial Update: Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating alternative dosing regimens of belantamab mafodotin in relapsed or refractory multiple myeloma; the study is active not recruiting and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-07